Jacques Blacher1, Emmanuel Sorbets2, Dominique Guedj Meynier3, Jean-Pierre Huberman3, Jacques Gauthier3, Serge Cohen3, Olivier Hoffman3. 1. Assistance Publique-Hôpitaux de Paris, Unité HTA, Prévention et Thérapeutique Cardiovasculaires, Centre de Diagnostic et de Thérapeutique, Hôtel-Dieu University Hospital, Université Paris Descartes, Place du Parvis Notre-Dame, 75004, Paris, France. jacques.blacher@aphp.fr. 2. AP-HP, Cardiology Department, Avicenne University Hospital, Paris 13 University, Bobigny, France. 3. Collège National des Cardiologues Français (CNCF), Paris, France.
Abstract
BACKGROUND AND OBJECTIVE: Atrial fibrillation, the most frequent form of arrhythmia, affects 5-15% individuals aged > 80 years. Stroke is a major risk for atrial fibrillation patients. The benefits of anticoagulant therapy clearly outweigh the risk of hemorrhage, even in the elderly. Despite the efficacy of warfarin, many eligible patients receive no prophylactic antithrombotic therapy. New generation oral anticoagulants compare favorably with vitamin K antagonists in the prevention of thromboembolic events and hemorrhage. These new agents are likely to influence the prescribing habits of anticoagulants in atrial fibrillation. The aim of this study to investigate both the frequency and the determining factors of anticoagulant prescriptions in AF patients aged ≥ 80 years and followed up by private-practice cardiologists in France. METHODS: The OCTOFA (Atrial Fibrillation in Octogenarians) Study assessed the anticoagulant prescribing habits of cardiologists in France. The volunteer cardiologists recruited all consecutive patients fulilling the inclusion criteria. RESULTS: Between June 2013 and September 2016, 89 cardiologists recruited 738 eligible patients: age ≥ 80 years, non-valvular atrial fibrillation, no other compelling indication for anticoagulation therapy, no recent acute coronary syndrome or stroke. Most (90.7%) patients were on oral anticoagulant therapy: vitamin K antagonist or non-vitamin K antagonist oral anticoagulants, low molecular weight heparin (1.4%), aspirin (5.7%), and no antithrombotic treatment (2.2%). Patients on vitamin K antagonists were older (p < 0.001), had lower renal function (p = 0.033), and had a more frequent history of myocardial infarction (p < 0.001), heart failure (p = 0.001), peripheral artery disease (p = 0.033), major hemorrhage (p = 0.025), and falls (p = 0.045). Four determining factors of anticoagulant prescriptions were statistically significant: high CHA2DS2-VASc score (p < 0.001), high HAS-BLED score (p < 0.001), age > 90 years (p = 0.001), and moderate/severe cognitive impairment (p = 0.002). CONCLUSIONS: Most private-practice cardiologists prescribe anticoagulant treatment according to current guidelines in elderly atrial fibrillation patients. Non-vitamin K antagonist oral anticoagulants represent a significant proportion of prescriptions.
BACKGROUND AND OBJECTIVE:Atrial fibrillation, the most frequent form of arrhythmia, affects 5-15% individuals aged > 80 years. Stroke is a major risk for atrial fibrillationpatients. The benefits of anticoagulant therapy clearly outweigh the risk of hemorrhage, even in the elderly. Despite the efficacy of warfarin, many eligible patients receive no prophylactic antithrombotic therapy. New generation oral anticoagulants compare favorably with vitamin K antagonists in the prevention of thromboembolic events and hemorrhage. These new agents are likely to influence the prescribing habits of anticoagulants in atrial fibrillation. The aim of this study to investigate both the frequency and the determining factors of anticoagulant prescriptions in AFpatients aged ≥ 80 years and followed up by private-practice cardiologists in France. METHODS: The OCTOFA (Atrial Fibrillation in Octogenarians) Study assessed the anticoagulant prescribing habits of cardiologists in France. The volunteer cardiologists recruited all consecutive patients fulilling the inclusion criteria. RESULTS: Between June 2013 and September 2016, 89 cardiologists recruited 738 eligible patients: age ≥ 80 years, non-valvular atrial fibrillation, no other compelling indication for anticoagulation therapy, no recent acute coronary syndrome or stroke. Most (90.7%) patients were on oral anticoagulant therapy: vitamin K antagonist or non-vitamin K antagonist oral anticoagulants, low molecular weight heparin (1.4%), aspirin (5.7%), and no antithrombotic treatment (2.2%). Patients on vitamin K antagonists were older (p < 0.001), had lower renal function (p = 0.033), and had a more frequent history of myocardial infarction (p < 0.001), heart failure (p = 0.001), peripheral artery disease (p = 0.033), major hemorrhage (p = 0.025), and falls (p = 0.045). Four determining factors of anticoagulant prescriptions were statistically significant: high CHA2DS2-VASc score (p < 0.001), high HAS-BLED score (p < 0.001), age > 90 years (p = 0.001), and moderate/severe cognitive impairment (p = 0.002). CONCLUSIONS: Most private-practice cardiologists prescribe anticoagulant treatment according to current guidelines in elderly atrial fibrillationpatients. Non-vitamin K antagonist oral anticoagulants represent a significant proportion of prescriptions.
Authors: N Cohen; D Almoznino-Sarafian; I Alon; O Gorelik; M Koopfer; S Chachashvily; M Shteinshnaider; V Litvinjuk; D Modai Journal: Stroke Date: 2000-06 Impact factor: 7.914
Authors: Francesc Formiga; Isabel Fort; Lluis Reig; Maria Jose Robles; Maria Carmen Espinosa; Daniel Rodriguez Journal: Gerontology Date: 2008-09-11 Impact factor: 5.140
Authors: S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf Journal: Lancet Date: 2006-06-10 Impact factor: 79.321
Authors: Annie Fourrier-Réglat; Cécile Droz-Perroteau; Jacques Bénichou; Fanny Depont; Michel Amouretti; Bernard Bégaud; Yola Moride; Patrick Blin; Nicholas Moore Journal: Epidemiology Date: 2008-03 Impact factor: 4.822